Chronopharmacokinetics: Current status

Clinical Pharmacokinetics

Volumn 35, Issue 2, 1998, Pages 83-94

  Bruguerolle, Bernard ^a,b  

^a School of Medicine   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; LIVER ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT;

BLOOD FLOW; CHRONOBIOLOGY; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; GLOMERULUS FILTRATION; KIDNEY BLOOD FLOW; KIDNEY TUBULE ABSORPTION; LIVER BLOOD FLOW; MICRODIALYSIS; PHYSIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PH; URINE PH;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CIRCADIAN RHYTHM; HUMANS; INTESTINAL ABSORPTION; LIVER; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0031854158     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199835020-00001     Document Type: Review

References (76)

1. Reinberg A. Concepts in chronopharmacology. Annu Rev Pharmacol Toxicol 1992; 32: 51-66
2. Reinberg A, Smolensky M. Circadian changes of drug disposition in man. Clin Pharmacokinet 1982; 7: 401-20
3. Bruguerolle B. Recent data in chronopharmacokinetics. Pathol Biol 1987; 35: 925-34
4. Levi F, Bruguerolle B, Hecquet B. Mechanisms and perspectives in clinical chronopharmacokinetics. Therapie 1989; 44: 313-21
5. Labrecque G, Belanger P. Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol Ther 1991; 52: 95-107
6. Bruguerolle B, Lemmer B. Recent advances in chronopharmacokinetics, methodological problems. Life Sci 1993; 52: 1809-24
7. Lemmer B, Bruguerolle B. Chronopharmacokinetics: are they clinically relevant? Clin Pharmacokinet 1994; 26: 419-27
8. Bruguerolle B, Desnuelle C, Jadot G, et al. Chronopharmacocinétique de l'indométhacine a effet prolongé en pathologie rhumatismale. Rev Int Rhum 1983; 13: 263-7
9. Bruguerolle B, Grignon S. Chronopharmacologie. Pathol Biol 1996; 44: 547-54
10. Bruguerolle B. Chronopharmacology. In: Touitou Y, Haus E, editors. Biological rhythms in clinical and laboratory medicine. Paris: Springer-Verlag, 1992: 114-37
11. Belanger P, Bruguerolle B, Labrecque G. Rhythms in pharmacokinetics: absorption, distribution, metabolism and excretion. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Heidelberg: Springer-Verlag, 1997: 177-204
12. Bruguerolle B. Chronopharmacokinetics aspects with special reference to cardiovascular drugs. In: Schmidt T, Engel B, Blumchen G, editors. Temporal variations of the cardiovascular system. Heidelberg: Springer-Verlag, 1992: 371-81
13. Shiga T, Fujimura A, Tateishi T, et al. The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects. Eur J Clin Pharmacol 1993; 44: 489-92
14. Lemmer B, Portaluppi F. Chronopharmacology of cardiovascular diseases. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Heidelberg: Springer-Verlag, 1997: 251-98
15. Demey C, Meineke I. Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA). Br J Clin Pharmacol 1992; 33: 179-82
16. Mustofa M, Suryawati S, Dwiprahasto I, et al. The relative bioavailability of diclofenac with respect of time of administration. Br J Clin Pharmacol 1991; 32: 246-7
17. Clench J, Reinberg A, Dziewanowska Z, et al. Circadian changes in the bioavailability and effects of indomethacin in healthy subjects. Eur J Clin Pharmacol 1981; 20: 359-69
18. Guissou P, Cuisinaud G, Llorca G, et al. Chronopharmacokinetic study of a prolonged release form of indomethacin. Eur J Clin Pharmacol 1983; 24: 667-70
19. Bruguerolle B, Barbeau G, Belanger P, et al. Chronokinetics of indomethacin in elderly subjects. Annu Rev Chronopharmacol 1986; 3: 425-8
20. Ollagnier M, Decousus H, Cherrah Y, et al. Circadian changes in the pharmacokinetics of oral ketoprofen. Clin Pharmacokinet 1987; 12: 367-78
21. Reinberg A, Levi F, Touitou Y, et al. Clinical pharmacikinetic changes in a sustained release preparation of ketoprofen (SRK). Annu Rev Chronopharmacol 1986; 3: 317-20
22. Decousus H, Ollagnier M, Cherrah Y, et al. Chronokinetics of ketoprofen infused intravenously at a constant rate. Annu Rev Chronopharmacol 1986; 3: 321-4
23. Srinivasu P, Rambhau D, Rao R. Chronopharmacokinetics of ketorolac in healthy volunteers. Clin Drug Invest 1995; 10: 110-6
24. Fujimura A, Kajiyama H, Kumagai Y, et al. Chronopharmacokinetic studies of propanofen and procainamide. J Clin Pharmacol 1989; 29: 786-90
25. Markiewicz A, Semenowicz K. Time dependent change in the pharmacokinetics of aspirin. Int J Clin Pharmacol Biopharm 1979; 17: 409-11
26. Reinberg A, Clench J, Ghata J, et al. Rythmes circadiens des paramétres de l'excrétion urinaire du salycylate (chronopharmacocinétique) chez l'homme adulte sain. C R Acad Sci 1975; 280: 1697-700
27. Couet W, Ingrand I, Millerioux L, et al. Etude chronopharmacocinétique du sulindac et de ses métabolites. Sem Hop Paris 1986; 62: 2677-82
28. Ohdo S, Nakano S, Ogawa N. Circadian changes of valproate kinetics depending on meal conditions in humans. J Clin Pharmacol 1992; 32: 822-6
29. Ronfeld RA, Wilner KD, Baris BA, et al. Sertraline: chronopharmacokinetics and the effect of coadministration with food. Clin Pharmacokinet 1997; 32: 50-5
30. Bruguerolle B, Giaufre E, Prat M. Temporal variations in transcutaneous passage of drugs: the example of lidocaine in children and in rats. Chronobiol Intern 1991; 8: 277-82
31. Bruguerolle B. Local anaesthetics. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Heidelberg: Springer-Verlag, 1997: 607-18
32. Reinberg A, Soudant E, Koulbanis C, et al. Circadian dosing time dependency in the forearm skin penetration of methyl and hexyl nicotinate. Life Sci 1995; 57: 1507-13
33. Ohdo S, Grass GM, Lee VH. Improving the ocular to systemic ratio of topical timolol by varying the dosing time. Invest Ophthalmol Vis Sci 1991; 32: 2790-8
34. Reinberg A, Schuller E, Deslanerie N, et al. Rythmes circadiens et circannuels des leucocytes, proteines totales, immunoglobulines A,G et M. Etude chez neuf adultes jeunes et sains. Nouv Presse Med 1977; 6: 3819-23
35. Bruguerolle B. Temporal variations in tissular and plasma protein binding of drugs with special references to their erythrocyte penetration as mechanisms involved in chronopharmacological effects. In: Vandendriessche T, Guisset JL, Petiau De Vries GM, et al., editors. Membranes and circadian rhythms. Heidelberg: Springer-Verlag, 1996: 159-67
36. Belanger PM. Chronobiological variation in the hepatic elimination of drugs and toxic chemical agents. Ann Rev Chronopharmacol 1988; 4: 1-46
37. Feuers R J, Scheving LE. Chronobiology of hepatic enzymes. Ann Rev Chronopharmacol 1988; 4: 209-54
38. Belanger PM, Labrecque G. Temporal aspects of drug metabolism. In: Lemmer B, editor. Chronopharmacology: cellular and biochemical interactions. Basel: Marcel Dekker, 1991: 15-34
39. Lemmer B, Nold G. Circadian changes in estimated hepatic blood flow in healthy subjects. Br J Clin Pharmacol 1991; 32: 624-9
40. Shaw GL, Falk RT, Caporaso NE, et al. Effect of diurnal variation on debrisoquine metabolic phenotyping. J Nat Cancer Inst 1990; 82: 1573-5
41. Cambar J, Cal JC, Tranchot J. Renal excretion: rhythms in physiology and pathology. In: Touitou Y, Haus E, editors. Biological rhythms in clinical and laboratory medecine. Paris: Springer-Verlag, 1992: 470-82
42. Reinberg A, Clench J, Ghata J, et al. Rythmes circadiens des parametres de l'excretion urinaire du salicylate (chronopharmacocinétique) chez l'homme adulte sain. C R Acad Sci (Paris) 1975; 280: 1697-700
43. Dettli L, Spring P. Diurnal variations in the elimination rate of a sulfonamide in man. Helv Med Acta 1966; 4: 921-6
44. Lemmer B, Scheidel B, Blume H, et al. Clinical chronopharmacology of oral sustained-release isosorbite-5-mononitrate in healthy subjects. Eur J Clin Pharmacol 1991; 40: 71-5
45. Lemmer B, Nold G, Behne S, et al. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol Int 1991; 8: 485-94
46. Lemmer B, Scheidel B, Behne S. Chronopharmacokinetics and chronopharmacodynamics of cardiovascular active drugs: propranolol, organic nitrates and nifedipine. Ann N Y Acad Sci 1991; 618: 166-81
47. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-6
48. Levi F. Chronopharmacology of anticancer agents. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Heidelberg: Springer-Verlag, 1997: 299-331
49. Bruguerolle B, Dupont M, Lebre P, et al. Bupivacaine chronokinetics in man after a peridural constant rate infusion. Annu Rev Chronopharmacol 1988; 5: 223-6
50. Ando Y, Minami H, Sakai S, et al. Is there a circadian variation in plasma concentrations of etoposide given by prolonged continuous infusion? Cancer Chemother Pharmacol 1996; 37: 616-8
51. Petit E, Milano G, Levi F, et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676-9
52. Sanders SW, Bishop AL, Moore JG. Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant infusion rate. Chronobiol Intern 1991; 8: 267-76
53. Philip-Joet F, Bruguerolle B, Lagier F, et al. Effects of a constant dose rate of terbutaline on circadian peak expiratory flow, heart rate and systolic arterial pressure in patients with asthma exacerbation. Respiration 1992; 59: 197-200
54. Coulthard KP, Birkett DJ, Lines DR, et al. Bioavailability and diurnal variation and absorption of sustained release theophylline in asthmatic children. Eur J Clin Pharmacol 1983; 25: 667-72
55. Uematsu T, Follath F, Voze S. Circadian changes in the absorption and elimination of theophylline in patients with bronchial obstruction. Eur J Clin Pharmacol 1986; 30: 309-12
56. Focan C, Doalto L, Mazy V, et al. Vindésine en perfusion continue de 48 heures (suivie de cisplatine) dans le cancer pulmonaire avancé: données chronopharmacocinétiques et efficacité clinique. Bull Cancer 1989; 76: 909-12
57. Johansen MJ, Newman RA, Madden T. The use of microdialysis in pharmacokinetics and pharmacodynamics. Pharmacotherapy 1997; 17: 464-81
58. Bruguerolle B. General concepts and new trends in chronopharmacology. In: Touitou Y, editor. Biological clocks: mechanisms and applications. International Congress of Chronobiology; 1998 Sep 7-11; Paris. North Holland: Elsevier Pergamon, 1998: 437-43
59. Ungerstedt U. Microdialysis principles and applications for studies in animal and man. J Intern Med 1991; 230: 365-73
60. Lehman JC, Jones TR, Mishra PK, et al. A novel microdialysis probe designed for clinical use: potential analytical and therapeutic applications. Acta Neurochir 1996; 67: 66-9
61. Scheiner LB, Stanski DR, Vozehet S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71
62. Aronson JK, Chappell MJ, Godfrey KR, et al. Modelling circadian variation in the pharmacokinetics of non-steroidal antiinflammatory drugs. Eur J Clin Pharmacol 1993; 45: 357-61
63. Shappell SA, Kearns GL, Valentine JL, et al. Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man. J Clin Pharmacol 1996; 36: 1051-63
64. Lemmer B. Chronopharmacological aspects of PK/PD modelling. Int J Clin Pharmacol Ther 1997; 35: 458-64
65. Reinberg A, Levi F, Smolensky M, et al. Chronokinetics. In: Hansch C, editor. Comprehensive medicinal chemistry. Oxford: Pergamon Press, 1990: 279-96
66. Hecquet B. Constant pharmacologic effect and chronopharmacology: theoretical aspects. Chronobiology Int 1986; 3: 149-54
67. Hecquet B, Sucche M. Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve. J Pharmacokinet Biopharm 1986; 14: 79-93
68. Hecquet B. Theoretical aspects of chronopharmacology. Annu Rev Chronopharmacol 1990; 6: 1-24
69. Gries JM, Benowitz N, Verotta D. Chronopharmacokinetics of nicotine. Clin Pharmacol Ther 1996; 60: 385-95
70. Langner B, Lemmer B. Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. Eur J Clin Pharmacol 1988; 33: 619-24
71. Lemmer B, Nold G, Behne S, et al. Chronopharmacology of oral nifedipine in healthy subjects and in hypertensive patients. Eur J Pharmacol 1990; 183: 521-26
72. 2-blockers and cardiovascular active-drugs. Adv Drug Deliv Rev 1991; 6: 83-100
73. Bruguerolle B, Philip-Joet F, Parrel M, et al. Unequal twice-daily sustained release theophylline dosing in chronic obstructive pulmonary disease. Respiration 1992; 59: 197-200
74. Bruguerolle B, Reinberg A, Levi F. Publicité médicale et chronopharmacologie. Biomed Pharmacother 1986; 40: 206-7
75. Bruguerolle B. Chronobiology for increasing drug sales: use, misuse and abuse. Biol Rhythms Res 1995; 26: 362
76. Bruguerolle B, Arnaud C, Levi F, et al. Physiopathological alterations of alpha 1 acid glycoprotein temporal variations: implications for chronopharmacology. In: Baumann P, Eap CB, Müller WL, et al., editors. Alpha I acid glycoprotein: genetics, biochemistry, physiological functions and pharmacology. New York: Alan R Liss, 1989: 199-214